What is Lyophilisation?
Lyophilisation or ‘freeze drying’ is the process by which water is removed from a product after it is frozen and placed under a vacuum, allowing the ice to change directly from solid to vapor without passing through a liquid phase. The process consists of three separate processes:
- Primary Drying (Sublimation)
- Secondary Drying (Desorption)
There are many benefits to using a lyophilised control including; improved product shelf-life and enhanced stability of volatile analytes. For example, many lyophilised controls have a shelf life of up to four years from the date of manufacture resulting in a reduction of costly new lot validation studies. Furthermore, lyophilised controls can be aliquoted and refrozen to extend the working stability of the product.
Reconstituting Lyophilised QC Material
The process of reconstitution involves adding a specified volume of distilled water to lyophilised QC material. The water should completely dissolve the lyophilised contents, giving a liquid solution, which is ready for analysis.
Reconstitution is a straightforward process, but requires a high level of precision. Small errors can have serious implications to the reconstituted material:
- If too much water is pipetted during reconstitution, the material will be heavily diluted and results will be lower than expected
- If too little water is pipetted during reconstitution, the material will not be sufficiently diluted, and results will be higher than expected
- If the correct volume of water is pipetted, but a small amount of water gets stuck in the pipette tip due to poor pipetting technique, results will be higher than expected
If a lyophilised control has been reconstituted incorrectly the contents of the vial will be wasted. It is therefore vitally important that controls are reconstituted with care.
Materials and Methods Required
The list of requirements for an accurate and consistent reconstitution technique is not extensive, but each requirement is vital. Labs should have:
- Calibrated volumetric pipettes
- Sterile, appropriately sized pipette tips
- Distilled water, or other reconstitution fluid as specified
- Technician with good pipetting technique
- Lyophilised QC stored according to manufacturer’s specifications
How to Reconstitute Lyophilised QC Material
Each different lyophilised control may require slightly different preparation, always refer to the instructions for use before reconstituting control material. The below guide provides a general overview of the reconstitution process, using the Randox Human Assayed Chemistry Premium Plus control (HN1530) as an example
- Place the vial of lyophilised QC on a flat surface, carefully remove the lid and the rubber stopper making sure not to spill any material
- Using a calibrated pipette and sterilised pipette tip, add exactly 5ml of distilled water directly into the QC vial, ensuring no water is left in the pipette tip, or on the rim/side of the vial
- Place the rubber stopper and lid firmly back onto the QC vial, and leave to stand for 30 minutes
- After 30 minutes, gently invert the QC vial 10-15 times to ensure the contents is completely dissolved, making sure to avoid the formation of foam. It is important that you DO NOT SHAKE the vial. Alternatively place the vial on a roller for 30 minutes to ensure the contents is thoroughly mixed
- Once satisfied all material has been completely dissolved, proceed to use the QC product in accordance with the ‘Control’ section of the individual analyser application
- Once finished, refrigerate any unused material. It is good practice to label the vial with the date of reconstitution to prevent the use of material outside of the recommended stability period
- Prior to reusing lyophilised material, mix the contents thoroughly by gentle inversion, as highlighted in Step 4
It is important to remember that there may be slightly different reconstitution requirements for different QC material. For this reason, it is vital that the instructions provided on the QC Kit Inserts are closely followed.
Reconstituting lyophilised QC can be time-consuming. Therefore, Randox Acusera offer convenient 5ml distilled water serum diluent to assist laboratories with reconstitution of lyophilised controls. These user-friendly pour over vials streamline the reconstitution process and eliminate the risk of pipetting errors.
If you have any further questions regarding lyophilised controls or would like to contact us, please do so by emailing us at email@example.com or use the contact us button provided.
Are you taking part in Dry January? Giving up alcohol can do your insides a lot of good, and it’s great news for your liver in particular. It may be that after the festive period our liver needs a little bit of rest!
Did you know that alcohol consumption across the UK increases by a staggering 41 percent more than the annual monthly average in December? That’s more than anywhere else in the world.
The effects of alcohol on your health really depend on how much you drink and how often, but as the statistics show, more of us increase our uptake of alcohol over the festive period.
So how does this impact our body?
The results of over indulging vary from a hangover, a poor night’s sleep, to causing an irregular heartbeat, and in some cases, excessive alcohol intake can lead to liver damage. This can be a very serious condition, given the liver’s vital role in the body.
The liver plays a central role in all metabolic processes. In fat metabolism, it breaks down fats and produces energy. When we intake alcohol or drugs, the liver metabolizes the drug and detoxifies chemicals. And it also makes proteins important for blood clotting and other functions.
Following these processes, the liver also secretes bile that ends up back in the intestines and helps the digestion of fats and oils, otherwise known as lipids.
As Randox Health Expert Dr. Gary Smyth explains:
“The liver is one of the most complex organs in the body and also one of the most important. Although it is very resilient, each time it has to filter alcohol some of its cells die. The liver can develop new cells, but abuse over a prolonged period reduces its ability to regenerate, causing serious damage.”
It is not just heavy drinking over years that can cause liver disease – binge drinking is also a culprit and can lead to your liver becoming fatty and inflamed. The best advice is to drink in moderation. Simple tips like taking a glass of water in-between alcoholic drinks are key to staying hydrated.
Know your units;
- According to drinkaware.co.uk, unit guidelines are now the same for men and women.
- Both are advised not to regularly drink more than 14 units a week
- This equates to 6 pints of 4% beer / 6 glasses of 13% wine / 14 glasses (25ml) of 40% spirits
- But don’t save up your 14 units, it’s best to spread evenly across the week.
- If you want to cut down the amount you’re drinking, a good way is to have several drink-free days each week.
- If you’ve had a heavy drinking session, avoid alcohol for 48 hours.
What does one unit of alcohol look like?
One unit of alcohol is the amount of alcohol an average adult can process within one hour so that so that there’s no alcohol left in their bloodstream.
One unit of alcohol equates to:
- 218ml of standard 4.5% cider
- 76ml of standard 13% wine
- 25ml of standard 40% whiskey
- 250ml of standard 4% beer
- 250ml of a standard 4% alcopop
How many units are in my drink?
- Small glass white / rosé / red wine (125ml 12%) = 1.5 units
- Standard glass white / rosé / red wine (175 ml 12%) = 2.1 units
- Large glass white / red / rosé wine (250ml 12%) = 3 units
- Pint of lager / beer / cider (5.2%) = 3 units
- Bottle of lager / beer / cider (330ml 5%) = 1.7 units
- Single small shot of spirits (25ml 40%) = 1 unit*
*taken from NHS Live Well Guidelines
Having your liver health checked after Christmas is a great way of tracking any changes that you may need to make to your lifestyle, for better or for worse – essential for helping you prevent liver disease and allowing you to take early action if it is diagnosed.
At Randox we offer a comprehensive menu of liver function tests to determine the health of your liver. Provided by Randox to a wealth of hospitals, laboratories and research facilities across the globe, these tests are also directly available to you, the consumer, via our Randox Health clinics.
- Alanine Aminotransferase (ALT) – an enzyme mainly found in the liver. Liver injury or disease will release ALT into the bloodstream, thus elevating serum ALT levels. Moderately high or mildly elevated ALT levels can be associated with chronic liver disease, such as cirrhosis, which is scarring of the liver.
- Aspartate Aminotransferase (AST) – an enzyme found predominantly in the heart, liver and skeletal muscles. Cell injury or disease will release AST into the bloodstream, thus elevating blood AST levels. Increased AST levels may be associated with hepatitis (inflammation of the liver), cirrhosis (scarring of the liver), or drug-induced liver injury.
- Gamma-Glutamyltransferase (GGT) – an enzyme found mainly in the liver. Increased levels of GGT in the blood may indicate bile duct injury, hepatitis (inflammation of the liver), cirrhosis (scarring of the liver), liver necrosis (death of liver tissue), liver tumours or the use of drugs that are toxic to the liver. A high GGT level is frequently associated with increased alcohol consumption, as this liver enzyme is involved in the breakdown and removal of alcohol from the body.
- Glutamate Dehydrogenase (GLDH) – an enzyme located within the mitochondria (energy-producing machinery) of cells, particularly within liver tissue. Significant liver cell damage may cause release of GLDH into the bloodstream. Toxic liver damage, liver cell necrosis (cell death) or hypoxic liver disease (where liver cells are deprived of oxygen) may cause an increase in GLDH. Measurement of GLDH in combination with other liver markers may help distinguish between different causes of liver dysfunction.
- Bilirubin – a yellowish-brown pigment found in bile (a fluid produced in the liver that facilitates digestion in the intestine). Increased levels may be associated with liver or bile duct blockage (eg due to gallstones), hepatitis (inflammation of the liver), cirrhosis (scarring of the liver), trauma to the liver, a drug reaction, long-term alcohol abuse or rare inherited disorders (eg Dubin-Johnson syndrome which is characterised by mild jaundice).
- Albumin – produced by the liver, albumin is the most abundant protein in the blood. Albumin plays in important role in maintaining blood pressure and transporting a wide variety of small molecules, such as hormones, vitamins and drugs, throughout the body. Various conditions are associated with decreased albumin levels, including kidney and liver diseases.
- Copper – an essential mineral that plays a part in many enzyme systems within the body. Excess or deficiency of copper is very rare, however raised copper levels may be caused by chronic liver disease or acute hepatitis (inflammation of the liver).
And when used in conjunction with the wide variety of other tests available within the world’s most comprehensive and personalised health testing menu, you can obtain an understanding of your full body health like never before.
That’s why we don’t test in isolation, which can give a patchy representation of your health and can fail to pick up on related symptoms elsewhere in the body. We test up to 350 tests across 25 areas of your health – giving you the power to take your health into your own hands.
Contact the Randox Health team today to determine the health of your liver, and of your body.
Call 0800 2545 130 or click here.
Pet Food companies worldwide are working towards constantly improving and maximising the quality of their product. The problematic topic of mycotoxin contamination in pet feed is quickly becoming a major cause for concern. This is due to the risk they pose for animal health and with the increasing prevalence of mycotoxins globally the focus is on pet food companies to meet EU and FDA regulations and maximise the quality of their product.
What are Mycotoxins?
Mycotoxins are naturally occurring metabolites that are produced by certain moulds and with the ability to develop and grow on a variety of crops they can affect large amounts of feed and increasingly, pet food. If a sample tests positive even for low levels of contamination the toxins are still strong enough to cause illness in animals, and if low levels are consumed over a long period of time this can result in chronic illnesses including; cancer, organ damage and neurological disorders.
The main mycotoxins of concern in pet food are;
- Deoxynivalenol (DON)
- Fumonisins (FUM)
- Zearalenone (ZEN)
- T-2 Toxin
Contamination can occur in any country around the world and at any stage of production. Herein lies the issue of how to prevent mycotoxin pollution, to tackle the issue head on and work towards a mycotoxin free product is the joint responsibility of feed producers, supply chain partners and quality control laboratories ensuring the complete safety of the product.
How can you tell if an animal has ingested pet food contaminated with mycotoxins?
In terms of animal health, mycotoxins can cause a variety of problems. Severity and symptoms can vary from animal to animal but general symptoms include; hyperactivity, vomiting, high temperature and loss of coordination. If you suspect your pet has been affected by mycotoxins you must bring them to the vet for immediate treatment.
The European Union currently regulate all the mycotoxins listed above and are subject to maximum or recommended residue limits. In the US, FDA regulations are limited to aflatoxins, DON and fumonisins, see table below for FDA regulations. If mycotoxin levels in feed fail to meet FDA standards, mass amounts of feed may need to be destroyed as grain producers are prohibited from mixing contaminated feed with clean feed to reduce the mycotoxin levels.
|Immature Animals||Aflatoxins||Corn/ peanut/ other ingredients||20 ppb|
|Adult Pets||Aflatoxins||Corn/ peanut/ cottonseed meal/ other ingredients||20 ppb|
|DON||Grain/ grain byproducts, not to exceed 40% of diet||5 ppm|
|Fumonisins||Corn/ corn byproducts, not to exceed 50% of the diet||10 ppm|
How do we tackle the problem?
Safe, reliable screening solutions for different variations of mycotoxins are available that can ensure only mycotoxin free feed is produced. Randox Food Diagnostics have created mycotoxin screening platforms as a response to increased levels of mycotoxins being found in feed globally.
The platforms use patented Biochip Array Technology (BAT) so pet food producers can test for multiple toxins from a single sample. Randox Food Diagnostics have a range of mycotoxin Biochip Arrays available with customised arrays available to suit the specific screening needs of certain producers. Each Biochip format uses a straightforward extraction process with a 50µl sample of feed, available tests include; Fumonisins, Ochratoxin A, Aflatoxin G1/G2, Aflatoxin B1, Paxiline, Ergot Alkaloids, Diacetoxyscirpenol, Deoxynivalenol, T2 Toxin and Zearalenone.
For more information on mycotoxin screening with Randox Food Diagnostics contact firstname.lastname@example.org
Chronic Kidney Disease (CKD) is a long term condition which involves the progressive loss of kidney function a late diagnosis can result in end stage renal disease requiring kidney dialysis or transplantation. Typically, CKD is result of a combination of other conditions which puts a strain on the kidneys, these conditions can include high blood pressure, diabetes and high cholesterol amongst many other ailments.1
Randox Biosciences are continually researching and developing new tests, targeting various health concerns around the world to improve diagnostics and health worldwide. Recently, our dedicated scientists have developed a new test, utilising our proprietary Biochip Array Technology (BAT) that simultaneously and quantitatively detects multiple early biomarkers associated with kidney damage allowing for earlier intervention and treatment, preventing further kidney damage.
We offer two multiplex Chronic Kidney Arrays as shown below:
Early detection provides those diagnosed with the opportunity to alter their lifestyle in order to improve their kidney and overall health, whether that is through the reduction of salt in their diet, increased physical activity and alcohol limitation.
To find out more about the Chronic Kidney Disease Arrays offered by Biosciences email email@example.com
1 NHS – https://www.nhs.uk/conditions/kidney-disease/
In 2002, Randox invented a worlds first; Biochip Array Technology, instantly changing the landscape of diagnostic testing forever. Biochip Array Technology is a multi-analyte platform which provides an unrivalled increase in patient information per sample. Instead of a patient sample needing to be subdivided for each test result, or in some cases re-collected, Biochip Array Technology offers a diagnostic patient profile with each patient sample.
How does it work?
Biochip Array Technology is a precision multiplex testing platform allowing for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
The biochip detection system is based on a chemiluminescent reaction. This is the emission of light, without heat, as a result of a chemical reaction. An enzyme is used to catalyse the chemical reaction on the biochip which generates the chemiluminescent signal. The light emitted from the chemiluminescent reaction that takes place in each DTR is simultaneously detected and quantified using a Charge-Coupled Device (CCD) Camera.
Each biochip has up to 49 Discrete Test Regions (DTR). This means that up to 44 tests can be carried out simultaneously. The additional DTR are reserved for internal quality control and visual reference, a unique Biochip Array Technology feature.
How is the technology applied?
With over £250 million invested into Biochip Array Technology research and development, Randox have launched a range of Biochip Array Technology immunoanalysers – The Evidence Series. This includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser is developed with boundary pushing engineering, designed to make financial, labour and time savings for the end user.
The Evidence Series has truly revolutionised diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
Randox Clinical laboratory Services (RCLS) is the latest offering from Randox, Built over 35 years of experience producing high quality IVD products, Randox Clinical Laboratory Services (RCLS), is dedicated to providing a clinical laboratory service designed to meet the time sensitive, bespoke requirements of research and clinical projects globally.
RCLS currently has four state of the art, fully functional ISO12025 accredited laboratories across the UK. They are situated in Liverpool, London and two in Northern Ireland, Hollywood and Randox Science Park in Antrim. RCLS looks to expand their team of experienced scientists, working towards further accreditations and furthermore setting up two additional labs in Dubai and Los Angeles. The addition of these purpose built labs will give RCLS the ability to increase output to both the health and research market.
Ann-Marie Jennings, Laboratory Manager for Randox Clinical Laboratory Services, discusses the Randox Biochip Array, RCLS’ abilities and confidence in testing;
“On our patented Randox Biochip Array Technology we can customize bespoke testing platforms based on the requirements of each drug development project, which can be a challenging process. From initial product development to clinical trial stages there can be a number of barriers and time constraints before drugs are successfully released to the public. We’re confident that our newly enhanced capabilities will benefit patients suffering from conditions in most need of research by offering pharmaceutical companies at the forefront of pioneering research, with the latest technological developments.”
Thanks to these state of art laboratories, RCLS will now be able to provide an increasingly wide range of testing services to Biotechnology, research and pharmaceutical companies delivering the testing services required to support their research and drug development projects.
With the ability to conduct an unrivalled range of health testing – haematology, biochemistry and immunoassay – all under one roof, the laboratory offers unparalleled support services to the dynamic and growing healthcare industry. With a greater understanding of human complexity, pharmaceutical companies are now focusing on developing safer drugs tailored to specific patient groups or sub-groups and the expansion plans in motion at RCLS will help these organisations bring new drugs to market faster.
If you would like more information on Randox Clinical Laboratory Services, please contact us by emailing us at firstname.lastname@example.org
Today, Northern Ireland’s Chief Medical Officer Dr. Michael McBride has stated that antibiotic resistance is now the greatest risk to human health and medicines worldwide. Dr. McBride said; “Currently 700,000 people die worldwide each year from drug resistant infections and this figure is forecasted to reach 10 million deaths by 2050, if the problem is ignored.”
It is rather alarming therefore that 70% of GPs admit that they prescribe antibiotics when they are unsure if they are treating a viral or bacterial infection. By prescribing antibiotics for viral infections, which can’t be combatted with antibiotics, patients are being exposed to antibiotics which are of no benefit.
John Lamont, Lead Scientist at Randox Laboratories, said that “Current diagnostic testing for respiratory infections takes at least 36 hours to confirm the nature of an infection, and they cannot name and categorise infections as bacterial or viral is the way our new respiratory test can.”
At Randox, our pioneering R&D teams have developed a revolutionary swab test for respiratory infections which indicates the cause of the infection and whether a patient needs antibiotics or not. This helps to limit the amount of patients who are prescribed antibiotics, reducing antibiotic resistance.
The Randox test, which can rapidly detect and identify the cause of 21 respiratory infections in just 5 hours, can also subsequently determine the appropriate antibiotic drug treatment for patients.
This test, if adopted by GP surgeries, could allow medical practitioners to make the correct treatment choice on the same day as examination and before patients have already begun a precautionary course of inefficient antibiotics. It would also have additional efficiency savings for the NHS, by eliminating the need for lengthy microbiology lab tests and unnecessarily prescribing drugs which are not needed. This new rapid and accurate test will give the GP confidence in their diagnosis of respiratory infections and will allow for quicker treatment if necessary, which benefits patient outcomes.
The test is also available as a Randox Health Cough, Cold & Flu offering, and can be carried out by booking an appointment with Randox Health at our clinics in Crumlin, Holywood or London, or by arranging the mobile clinic to visit you at your home or place of work.
So what action can we take to limit the looming antibiotic resistance crisis?
- Ask your GP if tests will be performed to make sure you even need antibiotics and that the correct antibiotic is prescribed.
- Take the antibiotics as prescribed. Make sure you complete the prescribed course, even when you start feeling better. This makes sure that all bacteria from your current infection are eradicated, leaving none behind that could potentially develop resistance to your antibiotic.
- Only take antibiotics prescribed for you; do not share or use leftover antibiotics. Taking the wrong medication will delay correct treatment and allow bacteria to multiply, and potentially develop a resistance to the antibiotic you are using incorrectly.
Find out more about the Cough, Cold & Flu Respiratory test here.
Book an appointment with one of our clinics, or arrange the mobile clinic, by phoning 0800 2545 130 or by clicking here.
For further information please contact the Randox PR team by email: email@example.com or phone 028 9442 2413
In advance of the highly anticipated Randox Health Grand National 2017, the race’s new sponsor is launching a nation-wide campaign to encourage people to take control of their health and wellbeing, with the help of legendary jockey AP McCoy.
Global healthcare company Randox Health is offering one lucky winner the chance to join AP on its elite team of brand ambassadors, which also includes Olympic Sailor Matt McGovern. The winner of the competition will receive the world’s most advanced personalised health check – the Randox Health Signature Programme, as well as tickets to the Randox Health Grand National 2018, and an iPad Pro.
Via Facebook, Twitter or Instagram, entrants have to submit a photograph and accompanying text to tell the world’s greatest jockey why they want to #FeelLikeAP and enjoy a healthier future.
AP McCoy has encouraged others to start thinking about their health and commented;
“I’m delighted to be involved with such a positive campaign, asking people to think about their health and why it is so important to them, and to take preventive action to secure it. The information I got from my Randox Health check showed I was on the path to getting diabetes and needed to address low calcium levels and malnutrition among other things which could – if left untreated – have been big problems. But I can take action now to prevent this.
“Some people may be inclined to wait until you feel ill before going to the doctor but it’s better to do what you can to prevent it from happening, if you can.”
Dr. Peter FitzGerald, Founder and Managing Director of Randox Health, launched the new health campaign by saying;
“AP McCoy has a special place in the hearts of millions of people across the world – those who shared his passion and were inspired by his commitment and drive. By spreading the Randox message of preventive health, he is giving back to those supporters by giving them the tools to live not just a long life but a healthy one too.
“Right across society, too many people suffer from preventable illnesses, and almost a quarter of all deaths under 75 in the UK are avoidable. The solution is to reduce the risk of becoming ill and we achieve that through preventive health. It’s no longer enough sto say you’re healthy today. The diagnostics exist and are being used in our Randox Health clinics to tell you how to be healthy in the future as well.
“This is not just a competition we are launching with AP, but a nationwide campaign which I hope will create a sea-change in how we view our health.”
To enter the #FeelLikeAP competition and be in with a chance to join AP as a Randox Health brand ambassador, win a Randox Health Signature Programme, 2 tickets to the Randox Health Grand National 2017, and an iPad Pro, you must:
- follow Randox Health on either Facebook, Instagram or Twitter
- upload a photo
- tell AP and Randox Health why your future health matters to you. Don’t forget to include the hashtag #FeelLikeAP.
More information about the #FeelLikeAP competition visit https://www.randox.com/feel-like-ap-mccoy/
For more information about Randox Health please contact Nicola McHugh or Amy McIlwaine in the Randox PR team by emailing firstname.lastname@example.org or phone 028 9442 2413
For the first time in the Grand National’s history a new trophy will be designed every year during the sponsorship with the global diagnostics company Randox Health. The first of the five new trophies will be unveiled at the highly anticipated Weights Evening Reception on Tuesday 14th February.
Today marks the final step of the 2017 trophy design, with its hallmarking at the prestigious Goldsmiths’ Company Assay Office, in the City of London, which has been hallmarking precious metals for over 700 years. This concluding stage in the design of the trophy has enabled its sponsor to release to the public for the first time some tantalising teaser pictures of what will be presented to the 2017 Randox Health Grand National winner.
In advance of the annual Weights Reception, over the next 14 days a series of images from the trophy will be released before the grand unveiling at the Victoria and Albert in London.
Dr. Peter FitzGerald, Founder and Managing Director of Randox Health, commented;
“Given that the Randox Health Grand National is such an iconic event it is fitting that each winner will receive an inimitable trophy; their own unique piece of history. To win this event, given the demanding nature of the course and the quality of the competition, requires preparation, stamina, skill and teamwork of the very highest standard. There is no other race in the world like this and we want to ensure the winner’s trophy, which will change each year, reflects the status of the achievement.”
The trophy has been created at workshops at the magnificent Burghley House in Stamford by Silversmith Shannon O’Neill, who described the silver 2017 trophy as an ornate work of art, laced with images depicting the speed, agility and excitement of jump racing, and decorated with a red stone.
“I’m incredibly honoured to have been given the opportunity to design and create a piece of art as important as the trophy for the Randox Health Grand National. Meeting the Randox requirement has been an exciting challenge – the brief was ambitious and we’re all delighted with the final outcome. That this is a unique piece makes it even more special. I look forward to its unveil in February and additionally to seeing the next four trophy designs over the coming years.”
Additionally, for the first time in history, each member of the winning team, made up of owner, trainer, jockey and groom will receive their own version of the trophy, a decision about which Ed Chamberlin, Lead Racing Presenter for ITV is delighted;
“Nothing comes close to the immense amount of passion, dedication, and teamwork that goes in to preparing for these big races, and for the biggest race of all, the Randox Health Grand National. From the stable staff in the yard to the punter at the bookies, the jockey training for the race of his life to the ground staff tending to the racecourse and the fences, in racing everyone has a very important role to play, whether that’s in front of the camera or behind the scenes. So I’m thrilled that Randox Health is paying tribute to the fact that the contributions of each member of the winning team are equally important.”
“For ITV it’s exciting to have an ambitious and innovative partner in the form of Randox Health for the world’s greatest race. Everything we do as racing broadcaster is about making the sport much more accessible and engaging with the public, and the revamping of the Randox Health Grand National trophy with this fun, teasing roll-out is a perfect launch for this.”
For more information about Randox Health please contact Nicola McHugh or Amy McIlwaine in the Randox PR team by emailing email@example.com or phone 028 9442 2413
Calls for more accurate diagnosis of people at risk of developing Type-2 diabetes have been supported by Randox, following a warning raised by an Oxford University study which looked into efforts to tackle the worsening epidemic of the condition.
The study, which was published in the British Medical Journal, examined results from the NHS’s programme which involves a screening test for pre-diabetes. The authors determined that the UK’s National Diabetes Prevention Programme is unlikely to have much impact because the blood tests used were inaccurate at detecting pre-diabetes, though these are currently the only ones available to doctors and patients. The study argues that if the screening is inaccurate then people will either be falsely reassured or receive incorrect diagnoses, which will not help the worldwide challenge to reduce people at risk of developing diabetes that continues to increase across the world.
It is estimated that Type-2 diabetes causes 22,000 early deaths every year in England alone. Across the UK over 3m people currently have the condition though experts say this will increase to 5m by 2025.
With current treatment taking up almost 9% of the annual NHS budget – roughly £8.8bn a year – the implications for future healthcare budgets are clear if this dangerous trend persists.
Global reagents Manger Susan Hammond said,
“Although we wholly back the NHS’s belief that positive lifestyle changes make crucial differences in people’s health and lives, we also believe that unless earlier and more accurate diagnostic screening is employed on a twin-track of treatment, this epidemic will continue to worsen. We welcome that this study highlights the fact that clinician’s s are currently limited in what they can use to tackle the threat posed by diabetes. There are emerging biomarkers they could be given access to, such as Adiponectin and determining a person’s risk of Metabolic Syndrome.”
Assessing Adiponectin levels allows doctors to calculate the amount of visceral fat stored around a patient’s organs. This deep fat, which is not visible to the naked eye, is linked to health problems including Type-2 diabetes. High levels of adiponectin equate to low levels of visceral fat which can be combated by improving your diet, exercise habits and even stress levels. Given that 70% of Type-2 diabetes can be prevented by lifestyle changes, there is strong correlation that by detecting low levels of Adiponectin and taking corrective and preventive action, it could results in a decrease in the numbers of people who develop the life altering condition.
In addition to a test for the Adiponectin biomarker, Randox Biosciences have created a Metabolic Syndrome Array that measures 12 markers associated with metabolic syndrome and cardiovascular disease. Metabolic Syndrome is a is a group of cardiovascular risk factors that affects over 20% of adults and results in a person being three times more likely to have a stroke or heart attack, and five times more likely to develop diabetes.
Mrs Hammond concluded,
“We would ultimately like to see all medical professionals who are at the forefront of patient care armed with the most accurate diagnostic tools available. Updating traditional practice may not be easy but we believe it is imperative to do so, if we are to effectively challenge this global epidemic.”
Randox remains focused on providing early diagnoses and preventing illnesses by providing innovative diagnostics tests that will continue to revolutionise the healthcare landscape.